Valion Bio Announces 1-for-25 Reverse Stock Split to Regain Nasdaq Compliance

What Happened Valion Bio, Inc. (VBIO) filed a Form 8‑K reporting a Board‑approved 1‑for‑25 reverse stock split of its common stock, effective 12:01 a.m. Eastern Time on August 31, 2026. The company says the move is intended to raise the trading price per share to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the $1.00 minimum bid price), after receiving a notice from Nasdaq on March 19, 2026 that it was below the minimum for 30 consecutive trading days and was given until September 15, 2026 to cure. The filing also notes a Certificate of Amendment to the charter was filed with Delaware on August 26, 2026, and a press release announcing the split was issued on August 27, 2026.

Key Details

• Reverse split ratio: 1-for-25; effective date: August 31, 2026 (shares trade on a split‑adjusted basis at market open).
• Trading symbol remains “VBIO”; CUSIP will change to 918942202.
• No fractional shares will be issued; fractional results will be rounded up to the nearest whole share (no cash payment for fractions).
• All outstanding options, warrants, convertible securities and reserved shares under the equity plan will be adjusted by dividing share counts by 25 and multiplying exercise/conversion prices by 25, per governing terms.
• Transfer agent/exchange agent: Odyssey Transfer and Trust Company. A press release is furnished as Exhibit 99.1 and the Certificate of Amendment is Exhibit 3.1 to the 8‑K.

Why It Matters The reverse split is a corporate action aimed at restoring compliance with Nasdaq’s $1.00 minimum bid requirement so Valion Bio can maintain its listing on The Nasdaq Capital Market. For shareholders, the split should not materially change each holder’s percentage ownership or voting power (aside from any rounding from fractional shares), but it will reduce the number of shares outstanding and increase the per‑share price and adjusted exercise prices for warrants and options. Investors should watch trading on and after August 31, 2026 for the split‑adjusted market price and any additional company updates about Nasdaq compliance.